SE9601091L - Use of a protein substance for the binding of steroid-like molecules - Google Patents
Use of a protein substance for the binding of steroid-like moleculesInfo
- Publication number
- SE9601091L SE9601091L SE9601091A SE9601091A SE9601091L SE 9601091 L SE9601091 L SE 9601091L SE 9601091 A SE9601091 A SE 9601091A SE 9601091 A SE9601091 A SE 9601091A SE 9601091 L SE9601091 L SE 9601091L
- Authority
- SE
- Sweden
- Prior art keywords
- bile
- treatment
- steroid
- beneficial
- injury
- Prior art date
Links
- 230000003637 steroidlike Effects 0.000 title abstract 2
- 239000000126 substance Substances 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 239000003613 bile acid Substances 0.000 abstract 4
- 230000009286 beneficial effect Effects 0.000 abstract 3
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 230000008030 elimination Effects 0.000 abstract 2
- 238000003379 elimination reaction Methods 0.000 abstract 2
- 230000002496 gastric effect Effects 0.000 abstract 2
- 230000000968 intestinal effect Effects 0.000 abstract 2
- 150000003431 steroids Chemical class 0.000 abstract 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 abstract 1
- 206010069703 Bile acid malabsorption Diseases 0.000 abstract 1
- 206010008635 Cholestasis Diseases 0.000 abstract 1
- 206010012735 Diarrhoea Diseases 0.000 abstract 1
- 206010018364 Glomerulonephritis Diseases 0.000 abstract 1
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 206010067125 Liver injury Diseases 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 206010056528 Neonatal cholestasis Diseases 0.000 abstract 1
- 208000012868 Overgrowth Diseases 0.000 abstract 1
- 206010057969 Reflux gastritis Diseases 0.000 abstract 1
- 206010047115 Vasculitis Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 231100000753 hepatic injury Toxicity 0.000 abstract 1
- 102000051631 human SERPINA1 Human genes 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 235000013336 milk Nutrition 0.000 abstract 1
- 239000008267 milk Substances 0.000 abstract 1
- 210000004080 milk Anatomy 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 208000037816 tissue injury Diseases 0.000 abstract 1
- 230000009261 transgenic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8125—Alpha-1-antitrypsin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The use of human alpha 1-antitrypsin as a foodstuff or as a medicament, utilizing its capacity to bind steroids and steroid-like substances, and transporting them in biological systems is described. Particularly the direct oral administration of the milk of transgenic animals containing abundant amounts (10-60 g/L) of human alpha 1-AT to reinstate a defect intestinal synthesis or to complement the normal physiological biosynthesis of alpha 1-AT is described. Such treatment will reduce the total body load of bile acids by increasing their gastrointestinal elimination. It is expected to be beneficial for bile acid related diseases such as all cholestatic liver diseases, and bile-reflux gastritis. Such treatment is expected to be particularly beneficial in cases of neonatal cholestasis, as newborns circulate large quantities of hydrophobic bile acids which cause liver injury and may contribute to injury of other tissues. It will be protective in cases where bile acids cause tissue injury such as vasculitis, glomerulonephritis, and inflammatory bowel disease. It will be beneficial against diarrhoea in intestinal bacterial overgrowth and bile acid malabsorption. Increased gastrointestinal elimination of the steroid structure may also reduce the total body load of cholesterol and thus be efficient in the treatment of hyperlipidemia.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9601091A SE9601091L (en) | 1996-03-21 | 1996-03-21 | Use of a protein substance for the binding of steroid-like molecules |
| EP97914726A EP0904102A1 (en) | 1996-03-21 | 1997-03-20 | Milk of transgenic animals containing human alpha 1-antitrypsin and use of human alpha 1-antitrypsin to treat bile acid related diseases |
| PCT/SE1997/000465 WO1997034628A1 (en) | 1996-03-21 | 1997-03-20 | Milk of transgenic animals containing human alpha1-antitrypsin and use of human alpha1-antitrypsin to treat bile acid related diseases |
| AU21864/97A AU2186497A (en) | 1996-03-21 | 1997-03-20 | Milk of transgenic animals containing human alpha1-antitrypsin and use of human alpha1-antitrypsin to treat bile acid related diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9601091A SE9601091L (en) | 1996-03-21 | 1996-03-21 | Use of a protein substance for the binding of steroid-like molecules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE9601091D0 SE9601091D0 (en) | 1996-03-21 |
| SE9601091L true SE9601091L (en) | 1997-09-22 |
Family
ID=20401887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE9601091A SE9601091L (en) | 1996-03-21 | 1996-03-21 | Use of a protein substance for the binding of steroid-like molecules |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0904102A1 (en) |
| AU (1) | AU2186497A (en) |
| SE (1) | SE9601091L (en) |
| WO (1) | WO1997034628A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2351943A1 (en) * | 1998-11-19 | 2000-06-02 | Ppl Therapeutics (Scotland) Limited | Stabilisation of milk from transgenic animals |
| US7030289B2 (en) | 1998-11-19 | 2006-04-18 | Ppl Therapeutics (Scotland) Ltd | Stabilization of milk from transgenic animals |
| WO2000044390A1 (en) * | 1999-02-01 | 2000-08-03 | John Lezdey | Treatment of bladder and gastrointestinal mastocytosis |
| AUPP971399A0 (en) * | 1999-04-12 | 1999-05-06 | Life Therapeutics Limited | Separation of plasma components |
| WO2009008120A1 (en) * | 2007-07-12 | 2009-01-15 | Yuichi Sugiyama | Agent and method for stabilizing membrane protein |
| WO2017145031A1 (en) | 2016-02-22 | 2017-08-31 | Novartis Ag | Methods for using fxr agonists |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873316A (en) * | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US5439824A (en) * | 1993-05-06 | 1995-08-08 | The United States Of America | Increased expression of α-1-antitrypsin in expression vectors through the inclusion of intron II |
-
1996
- 1996-03-21 SE SE9601091A patent/SE9601091L/en not_active Application Discontinuation
-
1997
- 1997-03-20 WO PCT/SE1997/000465 patent/WO1997034628A1/en not_active Application Discontinuation
- 1997-03-20 AU AU21864/97A patent/AU2186497A/en not_active Abandoned
- 1997-03-20 EP EP97914726A patent/EP0904102A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| SE9601091D0 (en) | 1996-03-21 |
| WO1997034628A1 (en) | 1997-09-25 |
| AU2186497A (en) | 1997-10-10 |
| EP0904102A1 (en) | 1999-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Russel | Elemental diets | |
| Banasiewicz et al. | Determination of butyric acid dosage based on clinical and experimental studies–a literature review | |
| Wilson et al. | Short-chain fatty acids promote the migration of colonic epithelial cells in vitro | |
| Booth et al. | Studies on the site of fat absorption: 2 Fat balances after resection of varying amounts of the small intestine in man | |
| NO20063328L (en) | Use of a fatty acid composition comprising at least one of EPA and DHA or combinations thereof | |
| WO2008066308A1 (en) | Food composition for increasing the satiety and satiation | |
| UA78699C2 (en) | Use of bile acid or bile salt fatty acid conjugates for decreasing cholesterol blood content, treating fatty liver, hyperglycemia, and diabetes | |
| Bowman et al. | Biotin absorption by distal rat intestine | |
| Gausserès et al. | [15N]-labeled pea flour protein nitrogen exhibits good ileal digestibility and postprandial retention in humans | |
| Al-Dahhan et al. | Sodium homeostasis in term and preterm neonates. II. Gastrointestinal aspects. | |
| SE9601091L (en) | Use of a protein substance for the binding of steroid-like molecules | |
| JP6166888B2 (en) | Pet food | |
| Finkel et al. | The effects of a pectin‐supplemented elemental diet in a boy with short gut syndrome | |
| Verdegem et al. | Effect of dietary NSP level and bile acid supplementation on nutrient digestibility and the bile acid metabolism in rainbow trout (Oncorhynchus mykiss) | |
| Hall et al. | Response of the organs of rabbits to feeding during the first days after birth | |
| Guilford | Nutritional management of gastrointestinal tract diseases of dogs and cats | |
| Sangild | Transitions in the life of the gut at birth | |
| McCollum et al. | The" vitamine" hypothesis and deficiency diseases: a study of experimental scurvy | |
| Gandarillas et al. | The domestic pig (Sus scrofa domestica) as a model for evaluating nutritional and metabolic consequences of bariatric surgery practiced on morbid obese humans | |
| Chinery et al. | Soy polysaccharide in an enteral diet: effects on rat intestinal cell proliferation, morphology and metabolic function | |
| ES2913336T3 (en) | Methods of using secretory IgA | |
| Hofmann | Targeting drugs to the enterohepatic circulation: lessons from bile acids and other endobiotics | |
| Guilford | New ideas for the dietary management of gastrointestinal tract disease | |
| WILLIAMS et al. | Short bowel syndrome—a case report in a dog and discussion of the pathophysiology of bowel resection | |
| KR100484328B1 (en) | Foods containing cocoa component |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NAV | Patent application has lapsed |
